The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of zanzalintinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).
 
Meghana Singh
No Relationships to Disclose
 
Naudia Jonassaint
No Relationships to Disclose
 
John Rhee
No Relationships to Disclose
 
Vikram Gorantla
Consulting or Advisory Role - AstraZeneca
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline; Guardant Health; Seagen
Speakers' Bureau - Amgen; Pfizer
 
Janie Zhang
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Ipsen
 
Dennis Hsu
No Relationships to Disclose
 
Stela Celaj
No Relationships to Disclose
 
Scott Biggins
No Relationships to Disclose
 
Satdarshan Monga
No Relationships to Disclose
 
Aatur Singhi
Honoraria - Foundation Medicine
 
David Geller
No Relationships to Disclose
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Autem Therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)